All In Biotech

Drug Trial Radar · NCT01991795

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).

Last checked: Nov 20, 2026Latest source record: Mar 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 19,271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

19,271

Actual

Start

Feb 10, 2014

Primary completion

Jan 25, 2019

Study completion Jan 25, 2019

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Ticagrelor 60 mgDrug

    Ticagrelor 60 mg bd taken orally as tablets

  • Ticagrelor placeboDrug

    Ticagrelor placebo bd taken orally as tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Cardiovascular (CV) Death, MI or StrokeTime frame: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.

Locations

1,237 sites in 43 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Fairhope, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Tuscumbia, Alabama

  • Research Site

    Cottonwood, Arizona

  • Research Site

    Glendale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Fremont, California

  • Research Site

    Fresno, California

  • Research Site

    Irvine, California

  • Research Site

    La Mesa, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Mission Hills, California

  • Research Site

    Newport Beach, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Stanford, California

  • Research Site

    Stockton, California

  • Research Site

    Tarzana, California

  • Research Site

    Torrance, California

  • Research Site

    Denver, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Greenwich, Connecticut

Showing 40 of 1,237 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.